ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

ACADIA Pharma reports robust Q3 earnings and outlines growth strategies

ACADIA Pharma's Q3 earnings reflect strong sales performance, a robust financial position, and a focus on advancing its pipeline assets for future growth.
The company's new CEO brings industry expertise and a vision for expansion, while challenges in market expansion and competition require strategic planning.
Opportunities for ACADIA Pharma lie in international expansion, pipeline development, and continued efforts to drive growth through effective commercial strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.

ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down

The shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) have received a decreased price target from $50 to $28. These are the details.

ACADIA Pharmaceuticals Stock Price: $28 Target (Down From $50) By Morgan Stanley

MILWAUKEE, April 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Acadia (NASDAQ: ACAD).  The investigation results from inaccurate statements Acadia may have made regarding its financial results, business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc.

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys

The Food and Drug Administration rejected Acadia Pharma's Nuplazid for patients with dementia-related psychosis on Monday, leading ACAD stock to plunge to its lowest point in two years. The post Acadia Stock Crashes After FDA Rejects Key Drug — Analyst Sees Huge Delay appeared first on Investor's Business Daily.

Acadia Stock Crashes After FDA Rejects Key Drug — Analyst Sees Huge Delay

Bio-Path Holdings

Cidara Therapeutics

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and Cidara Therapeutics, Inc. (NASDAQ: CDTX) are among the early movers in the biotech space. ACADIA Wilts On FDA Rejection: Acadia said the FDA has issued a complete response letter regarding its supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis.

Why Acadia Pharma, Bio-path And Cidara Are Moving Today

The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) fell by over 19% pre-market. This is why it happened.

ACADIA Pharmaceuticals Stock Price Fell Over 19% Pre-Market: Why It Happened

The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ: ACAD) regarding its supplemental marketing application (for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). In the CRL, Psychiatry's division cited a lack of statistical significance in some subgroups of dementia and insufficient numbers of patients with specific less common dementia subtypes.

Acadia Stock Drops After FDA CRL For Pimavanserin Application In Hallucinations and Dementia-Related Psychosis

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA issued a CRL to indicate that they have completed their review of the application and has determined that th

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

Supernus Pharmaceuticals

They've both taken a beating, but their fortunes may soon change.

These 2 Scrappy Biotechs Could Skyrocket in April

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Why Is Acadia (ACAD) Down 45% Since Last Earnings Report?

ACADIA Pharmaceuticals (ACAD) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: ACADIA Pharma

We believe that ACADIA Pharmaceuticals stock, a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades near $27 currently and it is, in fact, down 43% from its pre-Covid high of around $47 in February 2020 – before the.

ACADIA Pharmaceuticals Stock Now Looks Oversold At $27 Levels

New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether ACADIA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

DraftKings

H&R Block

Novartis

bluebird bio

Barnes & Noble Education

Pulmonx

SNDL Inc.

Vermilion Energy

With the trading day more than halfway over, the broad markets were pushing higher yet again.

DraftKings, H&R Block, Novartis and More Wednesday Afternoon Analyst Calls

Stitch Fix

The overall index finally regained some lost ground.

These 2 Nasdaq Stocks Were Surprise Losers in Tuesday's Market Rally

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) said late Monday it was notified by the Food and Drug Administration of deficiencies in its regulatory application to expand the label for pimavanserin, which goes by the brand name Nuplazid. The company is seeking approval for Nuplazid as a treatment option for dementia-related psychosis.

Why 2 Acadia Pharma Analysts Are Bracing For FDA Rejection Of Nuplazid In Dementia

Shares of Acadia Pharmaceuticals plummeted as much as 49% on Tuesday after the FDA communicated to the firm that it identified deficiencies in its supplemental new drug application for Nuplazid. Acadia was seeking to expand the use of Nuplazid to treat hallucinations and delusions associated with dementia-related psychosis. The drug is already approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Acadia plummets 49% after FDA decision dims chances of label expansion for key drug (ACAD)

Acadia Pharmaceuticals (ACAD) stock is taking a beating on Tuesday after revealing an update from the FDA for one of its drugs. The post ACAD Stock: The Bad News That Has Acadia Pharmaceuticals Plunging Today appeared first on InvestorPlace.

ACAD Stock: The Bad News That Has Acadia Pharmaceuticals Plunging Today

Boston, Massachusetts--(Newsfile Corp. - March 9, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it is investigating Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) for potential violations of the federal securities laws. After the markets closed on March 8, 2021, Acadia announced that on March 3, 2021, the FDA informed Acadia, as part of the FDA's ongoing review of Acadia's supplemental New Drug Application, that the FDA had "identified deficiencies...

SHAREHOLDER ALERT: Acadia Pharmaceuticals Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm

The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.

ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA

Shares of Acadia Pharmaceuticals Inc. plunged 42.1% to pace all premarket decliners Tuesday, in the wake of the company's announcement that the Food and Drug Administration found undisclosed deficiencies in its supplemental New Drug Application (NDA) for pimavanserin, a treatment for hallucinations and delusions associated with dementia-related psychosis. The company said late Monday that the FDA's identification of deficiencies precluded discussion of labeling and post-marketing requirements.

Acadia Pharmaceuticals stock leads premarket losers after FDA finds undisclosed 'deficiencies' in NDA

The stock price of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) fell by over 40% pre-market. This is why it happened.

ACAD Stock Price Fell Over 40% Pre-Market: Why It Happened

Acadia Pharmaceuticals said Monday the Food and Drug Administration notified it of deficiencies in its application for a psychosis drug. In response, ACAD stock plummeted.

Acadia Pharmaceuticals Crashes On FDA Setback For Psychosis Treatment

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongoing review of the Company's supplemental New Drug Application (sNDA), the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The FDA stated that the notification does not reflect a final decision

Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

News for ACADIA Pharma Stock (ACAD)